A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk myelodysplastic syndromes: the “MDS thermometer”

Table 5 Immunophenotypic alterations detected in PB monocytes from LR-MDS patients versus normal individuals (controls)

	LR-MDS (n = 14)	Controls (n = 14)
Increased CD56 expression in monocytes
CD14⁺CD56⁺ cells (% total CD14⁺ monocytes) (*)	15 (0–99)	7 (0–15)
Increased percentages of CD14⁺ 56⁺ cells (> 18.0% total CD14⁺ monocytes)	6 (43%)	0 (0%)
Severity
Mild: CD56⁺ cells]18%–23%]	1 (7%)	0 (0%)
Moderate: CD56⁺ cells [23%–28%]	1 (7%)	0 (0%)
Severe: CD56⁺ cells]28%–100%]	4 (29%)	0 (0%)
Decreased CD16 expression in monocytes
CD14⁺CD16⁺ cells (% total CD14⁺ monocytes) (**)	3 (0–8)	12 (4–28)
Decreased percentages of CD14⁺CD16⁺ cells (< 5.0% of total CD14⁺ monocytes)	9 (64%)	2 (14%)
Severity
Mild: CD16⁺ cells [2.5%–5.0%]	2 (14%)	2 (14%)
Moderate: CD16⁺ cells [1.25–2.5%]	1 (7%)	0 (0%)
Severe: CD16⁺ cells [0.00–1.25%]	6 (43%)	0 (0%)

Abbreviations: LR-MDS lower risk myelodysplastic syndromes, PB peripheral blood
Results are expressed as absolute and (relative) frequencies or as median (range) values
Percentages were approximated to the closest full unit
Mann-Whitney U test, LR-MDS patients versus controls: (*) P = 0.026; (**) P < 0.001

ISSN: 2052-1839